Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Zhenchong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1411-9382; OpenAlex author ID A5086792269. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2020: 1 paper · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 13

  1. ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependen… Co-author DOI 10.1016/j.drup.2026.101381↗
  2. LINC00476 cooperates with ARIH2 and suppresses pancreatic cancer progression by inducing VIM ubiquitination. Co-author DOI 10.1097/js9.0000000000003596↗
  3. LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4. Co-author DOI 10.1186/s13062-024-00463-4↗
  4. A hierarchical prognostic model for Co-diabetes pancreatic adenocarcinoma. Co-author DOI 10.1016/j.heliyon.2023.e21642↗
  5. Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of… Co-author DOI 10.1016/j.heliyon.2022.e11321↗
  6. Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1155/2022/4269733↗
  7. ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway. First author DOI 10.1186/s13046-022-02310-8↗
  8. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2021/6682697↗
  9. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. First author DOI 10.1155/2021/9949272↗
  10. Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Co-author DOI 10.1177/11795549211024149↗
  11. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. Co-author DOI 10.7150/jca.57082↗
  12. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Co-author PMID 34249426↗
  13. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Co-author DOI 10.1111/jcmm.15990↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chuanzhao Zhang · 12 shared papers, 2020–2026 · strength 1.77
  2. Shanzhou Huang · 12 shared papers, 2020–2026 · strength 1.77
  3. Baohua Hou · 12 shared papers, 2020–2026 · strength 1.77
  4. Zuyi Ma · 12 shared papers, 2020–2026 · strength 1.75
  5. Hongkai Zhuang · 10 shared papers, 2020–2024 · strength 1.34
  6. Zixuan Zhou · 10 shared papers, 2020–2024 · strength 1.34
  7. Qi Zhou · 5 shared papers, 2021–2026 · strength 0.86
  8. Shujie Wang · 4 shared papers, 2021–2023 · strength 0.58
  9. Yuanfeng Gong · 4 shared papers, 2021 · strength 0.48
  10. Zelong Wu · 2 shared papers, 2023–2024 · strength 0.36
  11. Yiping Zou · 3 shared papers, 2021 · strength 0.34
  12. Bowen Huang · 3 shared papers, 2021 · strength 0.34
  13. Qian Yan · 1 shared paper, 2026 · strength 0.26
  14. Shiye Ruan · 1 shared paper, 2026 · strength 0.26
  15. Jike Fang · 1 shared paper, 2026 · strength 0.26
  16. Shanzhou Huang · 1 shared paper, 2026 · strength 0.24
  17. Bo Chen · 1 shared paper, 2021 · strength 0.12
  18. Junchao Guo · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.